tiprankstipranks
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Ownership - Who Owns ACADIA Pharmaceuticals?

2,140 Followers

ACADIA Pharmaceuticals (ACAD) Ownership Overview

51.75%19.07%17.58%11.60%
51.75% Insiders
17.58% Other Institutional Investors
11.60% Public Companies and
Individual Investors
The ownership structure of ACADIA Pharmaceuticals (ACAD) stock is a mix of institutional, retail and individual investors. Approximately 36.65% of the company’s stock is owned by Institutional Investors, 51.75% is owned by Insiders and 11.60% is owned by Public Companies and Individual Investors.
The ownership structure of ACADIA Pharmaceuticals (ACAD) stock is a mix of institutional, retail and individual investors. Approximately 36.65% of the company’s stock is owned by Institutional Investors, 51.75% is owned by Insiders and 11.60% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jan 09, 2024
Stephen Davis
Ceo,director
Sold$111811
Oct 06, 2023
Stephen Davis
Ceo,director
Sold$1132323
Oct 06, 2023
Austin D. Kim
Evp,general Counsel, Secretary
Sold$359463

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Dec 31, 2023Bought$178748
Dec 31, 2023Bought$292122
Dec 31, 2023Bought$304583
Dec 31, 2023Bought$3162310

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
42,864,612Institution26.01%717,553,605
39,536,729Insider23.99%661,844,843
11,621,421Institution7.05%194,542,588
10,493,355Institution6.37%175,658,763
5,964,129Institution3.62%99,839,519
3,347,837Institution2.03%56,042,791
2,407,888Institution1.46%40,308,045
2,270,873Institution1.38%38,014,414
2,131,525Institution1.29%35,681,729
1,705,113Institution1.03%28,543,592

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
10,493,355Institution6.37%175,658,763
2,407,888Institution1.46%40,308,045
1,705,113Institution1.03%28,543,592
1,294,295Institution0.79%21,666,498
1,228,741Institution0.75%20,569,124
1,195,370Institution0.73%20,010,494
1,006,405Institution0.61%16,847,220
835,391Institution0.51%13,984,445
758,178Institution0.46%12,691,900
729,863Institution0.44%12,217,907

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,860,348Institution2.34%71,377,835
3,141,539Institution1.91%58,087,056
3,202,972Institution1.94%53,617,751
2,883,581Institution1.75%48,271,146
2,168,426Institution1.32%36,299,451
1,788,451Institution1.09%33,068,459
1,778,188Institution1.08%32,878,696
1,226,130Institution0.74%20,525,416
1,043,656Institution0.63%17,470,801
568,192Institution0.34%9,511,534

FAQ

Who Owns ACADIA Pharmaceuticals (ACAD)?
According to the latest TipRanks data, approximately 17.58% of the company's stock is held by institutional investors, 51.75% is held by insiders, and 11.60% is held by retail investors.
    What percentage of ACADIA Pharmaceuticals (ACAD) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 17.58% of ACADIA Pharmaceuticals (ACAD) stock is held by institutional investors.
      What percentage of ACADIA Pharmaceuticals (ACAD) stock is held by retail investors?
      According to the latest TipRanks data, approximately 11.60% of ACADIA Pharmaceuticals (ACAD) stock is held by retail investors.
        Who owns the most shares of ACADIA Pharmaceuticals (ACAD)?
        Felix Baker owns the most shares of ACADIA Pharmaceuticals (ACAD).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis